Search Results 41-50 of 36818 for B cell lymphomas
GEN3013, Epcoritamab Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma EPCORE™ NHL-1 · Overview · Participation eligibility.
It targets the B-cell lymphoma 2 (BCL-2) protein, which supports cancer cell growth and is overexpressed in many patients with mantle cell lymphoma. Venetoclax ...
The purpose of this study is to evaluate the safety and tolerability of STP938 as a single agent in adult subjects with R/R B-cell and T-cell lymphomas.
The purpose of this study is to determine how well SNS01-T is tolerated by relapsed or refractory multiple myeloma, B cell lymphoma or plasma cell leukemia ...
Participation eligibility · Large B-cell lymphoma with one or more of the following features: · Subjects must have a positive interim PET per the Lugano ...
An Effectiveness and Safety Study of Daratumumab in Relapsed/Resistant Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma. Print ...
Study of Lenzilumab and Axicabtagene Ciloleucel in Subjects with Relapsed or Refractory Large B-cell Lymphoma · Overview · Participation eligibility.
Although B cells and T cells can give rise to malignancies or lymphomas, T-cell lymphoma is the rarer disease, making up less than 15% of all Non-Hodgkin ...
The purposes of this study are to explore the therapeutic efficacy of BAFFR-CAR T cells in BAFFR-expressing B-cell hematologic malignancies including large B- ...
T-cell/histiocyte rich large B-cell lymphoma;; DLBCL associated with chronic inflammation;; Primary cutaneous DLBCL, leg type;; Epstein-Barr virus (EBV) + ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your gift can go twice as far to advance cancer research and care!